Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants.

Patel M, Chen J, McGrory S, O'Gorman M, Nepal S, Ginman K, Pithavala YK.

Invest New Drugs. 2019 Nov 14. doi: 10.1007/s10637-019-00872-7. [Epub ahead of print] Review.

PMID:
31728714
2.

Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.

Garrett M, Taylor T, Mould DR, Amantea MA, Chen Y, Ingrosso A, Pithavala YK.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1131-1141. doi: 10.1007/s00280-016-3164-x. Epub 2016 Oct 25.

PMID:
27783139
3.

Clinical Trial Simulations From a Model-Based Meta-Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy.

Zierhut ML, Chen Y, Pithavala YK, Nickens DJ, Valota O, Amantea MA.

CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):274-82. doi: 10.1002/psp4.12078. Epub 2016 May 15.

4.

Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.

Chen Y, Rini BI, Motzer RJ, Dutcher JP, Rixe O, Wilding G, Stadler WM, Tarazi J, Garrett M, Pithavala YK.

Target Oncol. 2016 Apr;11(2):229-34. doi: 10.1007/s11523-015-0389-2.

5.

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.

Rini BI, Melichar B, Fishman MN, Oya M, Pithavala YK, Chen Y, Bair AH, Grünwald V.

Ann Oncol. 2015 Jul;26(7):1372-7. doi: 10.1093/annonc/mdv103. Epub 2015 Feb 20.

PMID:
25701454
6.

Axitinib plasma pharmacokinetics and ethnic differences.

Chen Y, Suzuki A, Tortorici MA, Garrett M, LaBadie RR, Umeyama Y, Pithavala YK.

Invest New Drugs. 2015 Apr;33(2):521-32. doi: 10.1007/s10637-015-0214-x. Epub 2015 Feb 8. Review.

PMID:
25663295
7.

Effect of axitinib on the QT interval in healthy volunteers.

Ruiz-Garcia A, Houk BE, Pithavala YK, Toh M, Sarapa N, Tortorici MA.

Cancer Chemother Pharmacol. 2015 Mar;75(3):619-28. doi: 10.1007/s00280-015-2677-z. Epub 2015 Jan 15.

PMID:
25589220
8.

Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.

Chen Y, Rini BI, Bair AH, Mugundu GM, Pithavala YK.

Clin Pharmacokinet. 2015 Apr;54(4):397-407. doi: 10.1007/s40262-014-0207-5.

PMID:
25343945
9.

Pharmacokinetics of single-agent axitinib across multiple solid tumor types.

Tortorici MA, Cohen EE, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1279-89. doi: 10.1007/s00280-014-2606-6. Epub 2014 Oct 22.

PMID:
25336084
10.

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.

Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70. doi: 10.1007/s00280-014-2604-8. Epub 2014 Oct 15.

11.

Common questions regarding clinical use of axitinib in advanced renal cell carcinoma.

Borst DL, Arruda LS, MacLean E, Pithavala YK, Morgado JE.

Am J Health Syst Pharm. 2014 Jul 1;71(13):1092-6. doi: 10.2146/ajhp130581. Review.

PMID:
24939498
12.

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.

Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE.

Cancer. 2014 Sep 1;120(17):2694-703. doi: 10.1002/cncr.28766. Epub 2014 May 20.

13.

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.

Rini BI, Melichar B, Ueda T, Grünwald V, Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D, Kim S, Jonasch E.

Lancet Oncol. 2013 Nov;14(12):1233-42. doi: 10.1016/S1470-2045(13)70464-9. Epub 2013 Oct 18. Erratum in: Lancet Oncol. 2014 Jun;15(7):e253.

14.

Population pharmacokinetic analysis of axitinib in healthy volunteers.

Garrett M, Poland B, Brennan M, Hee B, Pithavala YK, Amantea MA.

Br J Clin Pharmacol. 2014 Mar;77(3):480-92. doi: 10.1111/bcp.12206.

15.

Clinical pharmacology of axitinib.

Chen Y, Tortorici MA, Garrett M, Hee B, Klamerus KJ, Pithavala YK.

Clin Pharmacokinet. 2013 Sep;52(9):713-25. doi: 10.1007/s40262-013-0068-3. Review.

PMID:
23677771
16.

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.

Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J, Motzer RJ.

J Clin Pharmacol. 2013 May;53(5):491-504. doi: 10.1002/jcph.73. Epub 2013 Mar 28.

17.

Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.

Pithavala YK, Chen Y, Toh M, Selaru P, LaBadie RR, Garrett M, Hee B, Mount J, Ni G, Klamerus KJ, Tortorici MA.

Cancer Chemother Pharmacol. 2012 Jul;70(1):103-12. doi: 10.1007/s00280-012-1888-9. Epub 2012 May 27.

PMID:
22644797
18.

A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers.

Chen Y, Jiang J, Zhang J, Tortorici MA, Pithavala YK, Lu L, Ni G, Hu P.

Int J Clin Pharmacol Ther. 2011 Nov;49(11):679-87.

PMID:
22011693
19.

Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.

Spano JP, Moore MJ, Pithavala YK, Ricart AD, Kim S, Rixe O.

Invest New Drugs. 2012 Aug;30(4):1531-9. doi: 10.1007/s10637-011-9697-2. Epub 2011 Jun 14.

PMID:
21670972
20.

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.

Pithavala YK, Tong W, Mount J, Rahavendran SV, Garrett M, Hee B, Selaru P, Sarapa N, Klamerus KJ.

Invest New Drugs. 2012 Feb;30(1):273-81. doi: 10.1007/s10637-010-9511-6. Epub 2010 Aug 26.

21.

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics.

Tortorici MA, Toh M, Rahavendran SV, Labadie RR, Alvey CW, Marbury T, Fuentes E, Green M, Ni G, Hee B, Pithavala YK.

Invest New Drugs. 2011 Dec;29(6):1370-80. doi: 10.1007/s10637-010-9477-4. Epub 2010 Jul 2.

22.

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.

Pithavala YK, Tortorici M, Toh M, Garrett M, Hee B, Kuruganti U, Ni G, Klamerus KJ.

Cancer Chemother Pharmacol. 2010 Feb;65(3):563-70. doi: 10.1007/s00280-009-1065-y. Epub 2009 Jul 15.

23.

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT Jr, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS.

J Clin Oncol. 2005 Aug 20;23(24):5464-73. Epub 2005 Jul 18.

PMID:
16027440
24.

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.

Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G.

J Clin Oncol. 2005 Aug 20;23(24):5474-83. Epub 2005 Jul 18.

PMID:
16027439
25.

Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers.

Hsyu PH, Pithavala YK, Gersten M, Penning CA, Kerr BM.

Antimicrob Agents Chemother. 2002 Feb;46(2):392-7.

26.

Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.

McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, Shibata S, Spicer D, Bissett D, Pithavala YK, Collier MA, Paradiso LJ, Roberts JD.

Clin Cancer Res. 2000 Jul;6(7):2677-84.

27.

A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial.

Jackson KA, Rosenbaum SE, Kerr BM, Pithavala YK, Yuen G, Dudley MN.

Antimicrob Agents Chemother. 2000 Jul;44(7):1832-7.

28.

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks.

Roberts JD, Shibata S, Spicer DV, McLeod HL, Tombes MB, Kyle B, Carroll M, Sheedy B, Collier MA, Pithavala YK, Paradiso LJ, Clendeninn NJ.

Cancer Chemother Pharmacol. 2000;45(5):423-7.

PMID:
10803927
29.

Use of the InteliSite capsule to study ranitidine absorption from various sites within the human intestinal tract.

Pithavala YK, Heizer WD, Parr AF, O'Connor-Semmes RL, Brouwer KL.

Pharm Res. 1998 Dec;15(12):1869-75.

PMID:
9892471
30.

Evaluation of gastrointestinal absorption and metabolism.

Zimmerman CL, Wen Y, Soria I, Pithavala YK.

Drug Metab Rev. 1997 Nov;29(4):957-75. Review. No abstract available.

PMID:
9421681
31.

Use of the deconvolution principle in the estimation of absorption and pre-systemic intestinal elimination of drugs.

Pithavala YK, Soria I, Zimmerman CL.

Drug Metab Dispos. 1997 Nov;25(11):1260-5.

PMID:
9351902
32.

Retinoid absorption from simple and mixed micelles in the rat intestine.

Pithavala YK, Odishaw JL, Han S, Wiedmann TS, Zimmerman CL.

J Pharm Sci. 1995 Nov;84(11):1360-5. Erratum in: J Pharm Sci 1997 Feb;86(2):267.

PMID:
8587056

Supplemental Content

Loading ...
Support Center